Response rates by line and type of salvage therapy
| . | All therapies . | HI . | LI . | LI + venetoclax . | ||||
|---|---|---|---|---|---|---|---|---|
| NPM1c . | NPM1wt . | NPM1c . | NPM1wt . | NPM1c . | NPM1wt . | NPM1c . | NPM1wt . | |
| All lines (N) | 206 | 1516 | 68 | 459 | 109 | 762 | 24 | 201 |
| CR (%) | 49 (24)∗ | 224 (15) | 32 (47)† | 95 (21) | 7 (6) | 87 (11) | 7 (29) | 34 (12) |
| CRi (%) | 53 (26)∗ | 272 (18) | 11 (16) | 73 (16) | 31 (28)∗ | 117 (15) | 10 (42) | 56 (20) |
| CR/CRi (%) | 102 (50)† | 496 (33) | 43 (63)† | 168 (37) | 38 (34) | 194 (26) | 17 (71)∗ | 90 (32) |
| S1 (N) | 132 | 953 | 52 | 313 | 63 | 443 | 13 | 140 |
| CR (%) | 42 (32)∗ | 178 (19) | 28 (48)† | 82 (26) | 6 (10) | 56 (13) | 5 (38) | 27 (19) |
| CRi (%) | 32 (24) | 175 (18) | 8 (19) | 49 (16) | 18 (29)∗ | 71 (18) | 5 (38) | 37 (26) |
| CR/CRi (%) | 74 (56)† | 353 (37) | 36 (67)∗ | 131 (42) | 24 (38) | 127 (29) | 10 (76)∗ | 64 (45) |
| S2 (N) | 85 | 707 | 20 | 193 | 52 | 396 | 9 | 87 |
| CR (%) | 12 (14) | 68 (10) | 6 (30) | 27 (14) | 4 (8) | 28 (7) | 1 (11) | 10 (11) |
| CRi (%) | 16 (19) | 84 (12) | 2 (10) | 26 (13) | 11 (21)∗ | 42 (11) | 3 (33) | 12 (14) |
| CR/CRi (%) | 28 (33)∗ | 152 (22) | 8 (40) | 53 (27) | 15 (29)∗ | 70 (18) | 4 (44) | 22 (25) |
| ≥S3 (N) | 83 | 615 | 18 | 161 | 48 | 358 | 14 | 60 |
| CR (%) | 6 (7) | 23 (4) | 2 (11) | 10 (62) | 1 (2) | 9 (3) | 3 (21)∗ | 2 (3) |
| CRi (%) | 14 (17) | 62 (10) | 3 (17) | 18 (11) | 6 (13) | 24 (7) | 5 (36) | 10 (17) |
| CR/CRi (%) | 20 (24)∗ | 85 (14) | 5 (28) | 28 (17) | 7 (15) | 33 (9) | 8 (57)∗ | 12 (20) |
| . | All therapies . | HI . | LI . | LI + venetoclax . | ||||
|---|---|---|---|---|---|---|---|---|
| NPM1c . | NPM1wt . | NPM1c . | NPM1wt . | NPM1c . | NPM1wt . | NPM1c . | NPM1wt . | |
| All lines (N) | 206 | 1516 | 68 | 459 | 109 | 762 | 24 | 201 |
| CR (%) | 49 (24)∗ | 224 (15) | 32 (47)† | 95 (21) | 7 (6) | 87 (11) | 7 (29) | 34 (12) |
| CRi (%) | 53 (26)∗ | 272 (18) | 11 (16) | 73 (16) | 31 (28)∗ | 117 (15) | 10 (42) | 56 (20) |
| CR/CRi (%) | 102 (50)† | 496 (33) | 43 (63)† | 168 (37) | 38 (34) | 194 (26) | 17 (71)∗ | 90 (32) |
| S1 (N) | 132 | 953 | 52 | 313 | 63 | 443 | 13 | 140 |
| CR (%) | 42 (32)∗ | 178 (19) | 28 (48)† | 82 (26) | 6 (10) | 56 (13) | 5 (38) | 27 (19) |
| CRi (%) | 32 (24) | 175 (18) | 8 (19) | 49 (16) | 18 (29)∗ | 71 (18) | 5 (38) | 37 (26) |
| CR/CRi (%) | 74 (56)† | 353 (37) | 36 (67)∗ | 131 (42) | 24 (38) | 127 (29) | 10 (76)∗ | 64 (45) |
| S2 (N) | 85 | 707 | 20 | 193 | 52 | 396 | 9 | 87 |
| CR (%) | 12 (14) | 68 (10) | 6 (30) | 27 (14) | 4 (8) | 28 (7) | 1 (11) | 10 (11) |
| CRi (%) | 16 (19) | 84 (12) | 2 (10) | 26 (13) | 11 (21)∗ | 42 (11) | 3 (33) | 12 (14) |
| CR/CRi (%) | 28 (33)∗ | 152 (22) | 8 (40) | 53 (27) | 15 (29)∗ | 70 (18) | 4 (44) | 22 (25) |
| ≥S3 (N) | 83 | 615 | 18 | 161 | 48 | 358 | 14 | 60 |
| CR (%) | 6 (7) | 23 (4) | 2 (11) | 10 (62) | 1 (2) | 9 (3) | 3 (21)∗ | 2 (3) |
| CRi (%) | 14 (17) | 62 (10) | 3 (17) | 18 (11) | 6 (13) | 24 (7) | 5 (36) | 10 (17) |
| CR/CRi (%) | 20 (24)∗ | 85 (14) | 5 (28) | 28 (17) | 7 (15) | 33 (9) | 8 (57)∗ | 12 (20) |